Publications by authors named "Apperloo E"
Objective: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes and high cardiovascular risk in the SURPASS-4 trial. To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials.
Research Design And Methods: This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Article Synopsis
- Hyperglycemia at admission is linked to complications and increased mortality, but strict glycemic control during hospitalization lacks strong evidence for benefits.
- While strict control can reduce postoperative infections, it also raises the risk of hypoglycemia, which is a separate risk factor for mortality.
- Switching from the ineffective sliding scale insulin regimen to a basal-bolus insulin approach may lead to better patient outcomes and lower workloads for healthcare providers.
Article Synopsis
- Semaglutide, a drug for type 2 diabetes, shows promise in reducing albuminuria and slowing kidney disease progression in patients with chronic kidney disease (CKD) in a double-blind clinical trial.
- The study involved 101 participants, comparing those receiving 2.4 mg of semaglutide weekly to a placebo, with a focus on changes in urine albumin-to-creatinine ratio after 24 weeks.
- Results indicated a significant 52.1% reduction in albuminuria for the semaglutide group, although gastrointestinal side effects were more common compared to the placebo group.
Article Synopsis
- SGLT2 inhibitors and GLP-1 receptor agonists both have positive effects on cardiovascular and kidney health in patients with type 2 diabetes, leading to a study comparing their benefits when used together or separately.
- A meta-analysis from various trials showed that SGLT2 inhibitors effectively reduced risks of major cardiovascular events and kidney disease progression for patients whether or not they were taking GLP-1 receptor agonists.
- The consistency of these benefits across different outcomes indicates that SGLT2 inhibitors can be beneficial for all diabetic patients, regardless of GLP-1 receptor agonist usage.
Background And Hypothesis: This post-hoc analysis explored the semaglutide effects on eGFR slope by baseline glycemic control, blood pressure (BP), body mass index (BMI), and albuminuria status in people with type 2 diabetes and high cardiovascular risk.
Methods: Pooled SUSTAIN 6 and PIONEER 6 data were analyzed for change in estimated glomerular filtration (eGFR) slope by baseline HbA1c (<8%/≥8%; <64 mmol/mol/≥64 mmol/mol), systolic BP (<140/90 mmHg/≥140/90 mmHg), and BMI (<30 kg/m2/≥30 kg/m2). SUSTAIN 6 data were analyzed by baseline urinary albumin: creatinine ratio (UACR; <30/30 - 300/>300 mg/g).
Aim: To evaluate the albuminuria-lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria.
Methods: Participants with type 2 diabetes, an estimated glomerular filtration rate (eGFR) of more than 30 ml/min/1.73m and an urinary albumin: creatinine ratio (UACR) of more than 3.
Objective: These post hoc analyses of the Semaglutide Treatment Effect in People with obesity (STEP) 1-3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the effects of semaglutide (up to 2.4 mg) on kidney function.
Research Design And Methods: STEP 1-3 included adults with overweight/obesity; STEP 2 patients also had type 2 diabetes.
Objectives: The ability to perceive soft speech by cochlear implant (CI) users is restricted in part by the inherent system noise produced by the speech processor, and in particular by the microphone(s). The algorithm "SoftVoice" (SV) was developed by Advanced Bionics to enhance the perception of soft speech by reducing the system noise in speech processors. The aim of this study was to examine the effects of SV on speech recognition and listening effort.
View Article and Find Full Text PDFAims: To assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating renin angiotensin aldosterone system (RAAS) inhibition, and to assess the association of response variability with cardiovascular outcomes.
Material And Methods: We performed an observational cohort study in patients with type 2 diabetes who started RAAS inhibition between 2007 and 2013 (n = 1600). Patients were identified from general practices in the Netherlands.